Age: 50.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Coronavirus infection, SARS-CoV-2 test
Clinical narrative: COVID Infection despite vaccine; This spontaneous case was reported by a patient and describes the occurrence of CORONAVIRUS INFECTION (COVID Infection despite vaccine) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037A22B and 067F21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Hypertension (treated with linosipril/HCTZ) and Sulfonamide allergy. Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL DIHYDRATE (PRINZIDE) from 2012 to an unknown date for Hypertension.   On 05-Apr-2021, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 26-Apr-2021, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) dosage was changed to 1 dosage form. On 17-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Oct-2022, received fifth dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) dosage was changed to 1 dosage form. On 11-Dec-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced CORONAVIRUS INFECTION (COVID Infection despite vaccine). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 14-Dec-2022 to 18-Dec-2022 for Coronavirus infection, at an unspecified dose and frequency. On 28-Dec-2022, CORONAVIRUS INFECTION (COVID Infection despite vaccine) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Dec-2022, SARS-CoV-2 test: Positive. On 13-Dec-2022, SARS-CoV-2 test: Positive. On 18-Dec-2022, SARS-CoV-2 test: Negative. On 26-Dec-2022, SARS-CoV-2 test: Positive. On 28-Dec-2022, SARS-CoV-2 test: Negative.         The patient reported that the patient received 5 doses of COVID Vaccines and most recent dose was Pfizer Bivalent (BNT162B2 OMI BA.4-5) booster on 15-Oct-2022.  On 11-Dec-2022, patient felt ill (cold/flu symptoms).  Last dose of Paxlovid was on 18-Dec-2022, and first day with negative lateral flow after the Paxlovid course was on 19-Dec-2022 or Day 6 (first day after completing the course). On 25-Dec-2022, patient felt ill again (cold/flu symptoms) and rebound COVID symptoms (headache, cough, sore throat, nasal drip, mild fever, fatigue, diminished smell) with positive lateral flow antigen test on 26-Dec-2022. The patient was not hospitalized neither treated after rebound COVID symptoms after the paxlovid. On 03-Jan-2022, symptoms resolved.   Most recent FOLLOW-UP information incorporated above includes: On 07-Feb-2023: Significant follow up received. Deleted classification tracking only, updated reporter details, medical history, added laboratory tests, updated suspect product from paxlovid to Moderna vaccine, added co-suspect, updated concomitant medication, added treatment drug, updated event details (updated event verbatim, event coding from COVID-19 rebound to coronavirus infection, event onset date, outcome and added end date) and narrative.